Brain penetrating neuroprotectant that attenuates MPTP induced motor deficits, prevents neurodegeneration and suppresses microglial activation in the substantia nigra. Mechanistically, PTIQ effectively suppresses expression of MMP-3 (IC50 value 60 nM in stressed dopaminergic cells), and NO production (IC50 value <100 µM in LPS stimulated BV-2 cells). PTIQ also inhibits IL-1β, TNF-α (IC50 value 6.5 µM) and COX-2 (IC50 value 9.3 µM) and blocked nuclear translocation of NF-κB, yet it shows no inhibition of hERG channels or CYP isozyme activities.